31st EASDec Annual Meeting, 28th – 30th October 2021, Odense, Denmark.
Download PROGRAMME as PDF(178.57 KB)
THURSDAY, 28TH OCTOBER 2021
| 12:30 | Registration and lunch |
| 13:45 | How to navigate physically and virtually at the EASDec 2021 hybrid meeting |
| Chair of Local Organizing Committee, Professor Jakob Grauslund, Odense | |
| 14:00 | The Moonshot initiative |
| Professor Tom Gardner, Ann Arbor | |
| |
|
| 14:15 | Satellite Symposium: Diabetes and diabetic macular oedema – where are we today? |
| EASDec_Novartis_Symposium.pdf | |
| Novartis | |
| Moderator: Professor Jakob Grauslund, Odense | |
| Welcome and introduction | |
| Professor Jakob Grauslund, Odense | |
| Diabetes from the endocrinologist’s perspective: what is important for the ophthalmologist to know? | |
| VIRTUAL PRESENTATION | |
| Professor Mikael Rydén, Stockholm | |
| Diabetes from the ophthalmologist´s perspective: what is important for the endocrinologist to know? | |
| Professor Jakob Grauslund, Odense | |
| Discussion | |
| All | |
| 15:15 | Highlights and future directions from the 5th conference of Screening for Diabetic Retinopathy in Europe (www.drscreening2005.org.uk) |
| Moderators: Professor Tunde Peto, Belfast, and Dr Caroline Styles, Dunfermline | |
| 16:00 | Break |
| 16:30 | Satellite Symposium: Inflammation and the diabetic eye |
| EASDec_symposium_digital_flyer_1.pdf | |
| Alimera Sciences | |
| Chair: Professor Simon Harding, Liverpool | |
| Welcome & Introduction | |
| Professor Simon Harding, Liverpool | |
| Neuroinflammation: A key player in diabetic retinopathy/diabetic macular edema | |
| Professor Rafael Simó, Barcelona | |
| Imaging biomarkers to define DME chronicity and support therapeutic decision-making in DME | |
| Professor Stela Vujosevic, Milan | |
| Assessing the long-term safety and visual outcomes following corticosteroid therapy in patients with DME | |
| Professor Tunde Peto, Belfast | |
| Q&A | |
| All | |
| 17:30 | Satellite Symposium: Expanding Diabetic Eye Disease Detection and Management with Ultra-widefield Imaging |
| Optos | |
| Chair: Professor Tunde Peto, Belfast | |
| The Essential Role of Ultra-widefield in all Diabetic Eye Clinics | |
| Dr Stela Vujosevic, Milan | |
| Ultra-widefield Fluorescein Angiography: What Lies Unseen? | |
| VIRTUAL PRESENTATION | |
| Dr Paolo Silva, Boston | |
| The Role of the Peripheral Retina in Diabetic Retinopathy: From Basic Science to Town Planning | |
| Ms Laura Cushley (PhD Researcher), Belfast | |
| Virtual Diabetic Retinopathy Clinics, Artificial Intelligence and UWF-Guided Swept Source OCT | |
| Professor Tunde Peto, Belfast | |
| 18:30 | Official opening of EASDec |
| President of EASDec, Professor Rafael Simó, Barcelona | |
| Chair of Organizing Committee, Professor Jakob Grauslund, Odense | |
| 18:45 | Annual Meeting Welcome Reception (see Social Events for further information) |
| HC Andersen's House | |
| Hans Jensen Stræde 45 (100 meters from conference venue) | |
| Dress code: Casual | |
| Social event registration needed for participation | |
| A culinary fairy tale experience: | |
| 18:45 Welcome and drink | |
| 18:50 Exhibition and appetizers | |
| 19:30 Buffet (drinks included) | |
| 21:00 | End of the day |
FRIDAY, 29TH OCTOBER 2021
| 08:00 | Registration |
| 09:00 | Introduction and welcome |
| President of EASDec, Professor Rafael Simó, Barcelona | |
| Chair, Local Organizing Committee, Professor Jakob Grauslund, Odense | |
| 09:15 | Session 1: Experimental and translational research in diabetic eye complications |
| Chairs: Professor Reinier Schlingemann, Amsterdam, and Associate Professor Patrice Fort, Ann Arbor | |
| 09:16 | Topical ocular administration of sitagliptin, a DPP-4 inhibitor, prevents the downregulation of neuroretinal presynaptic proteins induced by diabetes (abstract 30) |
| Dr Cristina Hernandez, Barcelona | |
| 09:27 | Characterization of a new immortalized human microglial cell line and its pro-inflammatory activation (abstract 35) |
| Dr Aurora Mazzeo, Torino | |
| 09:38 | Towards a better understanding of PLVAP in vascular permeability: a proteomic approach to identify interacting partners of PLVAP (abstract 95) |
| Ms Esmeralda Bosma, Amsterdam | |
| 09:49 | Mapping the daily rhythmic transcriptome in the diabetic retina (abstract 68) |
| VIRTUAL PRESENTATION | |
| Dr Eleni Beli, Belfast | |
| 10:00 | mmunomodulation of microglia/macrophage interaction and its effect in diabetic retinopathy progression (abstract 55) |
| Ms Fatima Cano-Cano, Cadíz | |
| 10:11 | Winner of the EASDec Young Investigator Award in honour of Anne-Katrin Sjolie |
| Circadian clocks in diabetic retinal endothelial cells (abstract 70) | |
| VIRTUAL PRESENTATION | |
| Ms Hanagh Winter, Belfast | |
| 10:22 | Session conclusions by the moderators |
| 10:25 | Coffee break |
| 10:40 | Session 2: Epidemiology of ocular and systemic complications in diabetes |
| Chair: Professor Morten Moe, Oslo, and Professor Simon Harding, Liverpool | |
| 10:41 | Free-registration award-winning abstract for young scientist |
| Five-year incidence and progression of age-related macular degeneration in people with diabetes (abstract 80) | |
| Ms Dewi Romdhoniyyah, Liverpool | |
| 10:52 | Relationship between diabetic retinopathy and systemic neurodegenerative diseases: a systematic review and meta-analysis (abstract 16) |
| Professor Jakob Grauslund, Odense | |
| 11:03 | Non-attendance at diabetic eye screening in the Danish nationwide screening program (abstract 50) |
| Dr Anne Thykjær, Odense | |
| 11:14 | Association between diabetic retinopathy and glaucoma: results from a national screening program (abstract 41) |
| Dr Signe Sperling, Odense | |
| 11:25 | Prevalence and progression of diabetic retinopathy and macular edema during pregnancy in women with type 1 and type 2 diabetes (abstract 51) |
| Professor Elisabeth Mathiesen, Copenhagen | |
| 11:36 | Do systematic diabetic retinopathy screening programmes prevent severe sight impairment? (abstract 91) |
| Dr Caroline Styles, Dunfermline | |
| 11:47 | Session conclusions by the moderators |
| 11:50 | Eva Kohner Lecture: Detecting diabetic retinopathy – timing is everything |
| Chair: Professor Tunde Peto, Belfast | |
| Awardee: Professor Simon Harding, Liverpool |
|
| 12:35 | Lunch |
| 12:35-13:00: Poster presenters | |
| 13:00-13:30: All | |
| 13:00 | Session 3: Poster session |
|
|
1 - Experimental research
Free-registration award-winning abstract for young scientist 1-02: Correlation between the aqueous humor proteome and severity of diabetic macular edema (abstract 28)
2 – Diabetic eye screening
Free-registration award-winning abstract for young scientist Free-registration award-winning abstract for young scientist 2-03: A qualitative study on barriers and enablers to uptake of diabetic retinopathy screening by people with diabetes in the western province of Sri Lanka (abstract 83) 2-04: Inclusion of diabetic retinopathy screening strategies in national level diabetes care planning in low and middle-income countries: a scoping review (abstract 67) 2-05: Out of hours diabetic eye screening – a high risk group (abstract 72) 2-06: Diabetic retinopathy in pregnancy: screening attendance rates and development of disease (abstract 25) Free-registration award-winning abstract for young scientist 2-08: Treatment and follow up of patients graded as R3 (proliferative retinopathy) by diabetic retinopathy screening programme (DRSP) in Belfast, Northern Ireland (abstract 59) 2-09: Diabetic retinopathy screening in individuals with severe mental illness (abstract 20) 2-10: Diabetic eye screening outcomes after non-attendance for three or more years (abstract 27) 2-11: Diabetes-related blindness between 1999 and 2018 in Denmark (abstract 92) 2-12: A retrospective analysis of factors affecting attendance at the Northern Ireland Diabetic Eye Screening Programme in young people with diabetes aged 12-26 (abstract 38) 2-13: Impacts on eye health for patients who fail to attend hospital ophthalmology appointments (abstract 88) 2-14: Updating a diabetic eye screening programme - a long and winding road (abstract 79)
3 - Epidemiology
3-01: Diabetic retinopathy and risk of prevalent and 5-year incident cardiovascular disorders in type 2 diabetes (abstract 37) 3-02: Characteristic features of diabetic retinopathy (DR) in UK BIOBANK (UKBB) (abstract 75) 3-03: Characteristics of diabetic retinopathy in the Funen Diabetes Database based on latent class analysis (abstract 61) 3-04: Progression to proliferative diabetic retinopathy in the Danish Registry of Diabetic Retinopathy (abstract 64) 3-05: Relationship between diabetic retinopathy and primary open-angle glaucoma 3-06: Inverse cross-sectional and longitudinal relations between diabetic retinopathy and obstructive sleep apnea in type 2 diabetes: results from a national screening program (abstract 13) Free-registration award-winning abstract for young scientist 3-08: Diabetic retinopathy as a potential marker of protection of prevalent and incident migraine: results from a national cohort study (abstract 14) 3-09: Diabetic retinopathy and chronic respiratory failure: a national register-based cohort study (abstract 34) 3-10: Diabetic retinopathy as a potential marker of Parkinson’s disease: results from a nationwide register-based cohort study (abstract 19) 3-11: Diabetic retinopathy and risk of major depression: bidirectional results from a Danish register-based nationwide cohort study (abstract 33)
4 - Clinical studies
4-01: Disorganisation of Retinal Inner Layers (DRIL) in participants with diabetic macular oedema: The RELIGHT Study (abstract 96) 4-02: Risk of progression of type 2 diabetes individuals with non-proliferative retinopathy: Characterization of phenotypes in a 1-year follow-up study (abstract 36) 4-03: Comparison of mean HbA1c value and ΣexcessA1C index as predictors of retinopathy development at different diabetes duration (abstract 63) 4-05: Subjective visual disturbances in relation to fluctuating blood glucose levels in adult patients with diabetes mellitus: results from a pilot study (abstract 43) 4-06: Is visual function altered in people with uncomplicated type 2 diabetes or with early diabetic retinopathy? (abstract 71) 4-08: Dry eye symptoms and signs in patients with type 2 diabetes (abstract 97) 4-09: The statistician will see you now – how to make the best of a scarce resource (abstract 77)
5 - Retinal imaging
5-01: The retinal oxygen saturation can be used to differentiate retinal neovascularisations from intraretinal microvascular abnormalities (IRMAs) in diabetic retinopathy (abstract 90) 5-02: The importance of optical coherence tomography (OCT) for identification of clinically significant macular oedema (CSMO) in UK BIOBANK (UKBB) (abstract 78) 5-03: Comparison of different metrics for the identification of capillary closure in diabetic retinopathy using OCTA (abstract 57) 5-04: Suspected diabetic retinopathy (DR) related changes in UK BIOBANK (UKBB) (abstract 103) 5-05: Retinal vessel density, vessel diameter and oxygen saturation are associated with non-proliferative diabetic retinopathy in young patients with type 1 diabetes (abstract 65) 5-06: Localization of retinal lesions in diabetic retinopathy in a virtual ocular learning platform (VIOLA) (abstract 73) 5-07: Agreement between experts in the detection of diabetic retinopathy associated lesions in a virtual ocular learning platform (VIOLA) (abstract 18) Free-registration award-winning abstract for young scientist
6 - Automated screening
6-01: Detection of diabetic retinopathy lesions using deep learning based semantic segmentation in retinal 45 degrees 6-field images (abstract 76) Free-registration award-winning abstract for young scientist 6-03: Comparing SIVA and VAMPIRE for vascular geometric findings in patients with type 1 diabetes (abstract 26) 6-04: CHIldren Living with Diabetes See and Thrive with AI Review: CHILDSTAR (abstract 86) 6-05: Creating artificially training data for AI detection of retinal microaneurysms (abstract 81) 6-06: Performance evaluation of software-assisted diabetic retinopathy screening (abstract 105)
7 - Medical and surgical treatment of diabetic retinopathy
7-01: Pretraining on abstract modules on a virtual reality vitreoretinal simulator is a waste of time (abstract 56) Free-registration award-winning abstract for young scientist 7-03: Treating diabetic macular oedema: 12-weeks intervals in the first year (abstract 104) 7-05: Functional and structural efficacy of a novel combinational therapy of aflibercept and timely focal/grid photocoagulation in diabetic macular edema: do clinical study results compare favorably with a standard-of-care treated real-life population? (abstract 32) 7-08: Assessment of complications during the late postoperative period for patients with diabetes mellitus after drainage surgery of secondary neovascular glaucoma (abstract 49) |
| 15:00 | Keynote lecture: Translating epidemiological studies into clinical care in diabetes |
| VIRTUAL PRESENTATION | |
| Professor Ryo Kawasaki, Osaka | |
| 15:30 | Session 4: Clinical studies and novel treatments of diabetic retinopathy |
| Chairs: Dr Stela Vujosevic, Milan, and Professor Tom Gardner, Ann Arbor | |
| 15:31 | The levels of placental growth factor and other proteins in the vitreous of patients undergoing diabetic vitrectomy and the effect of bevacizumab as compared to aflibercept pre-treatment (abstract 93) |
| Dr Ingeborg Klaassen, Amsterdam | |
| 15:42 | The risk for developing vision threatening retinopathy after cataract surgery in diabetic patients depends on the post-operative follow-up time (abstract 98) |
| Professor Toke Bek, Aarhus | |
| 15:53 | Are there still indications for macular laser in diabetic macular oedema? (abstract 48) |
| Ms Angela Dale, Gloucestershire | |
| 16:04 | Effect of calcium dobesilate in patients with subclinical diabetic macular edema: the CADODIAME study (abstract 23) |
| Dr Olga Simó-Servat, Barcelona | |
| 16:15 | Factors associated with the response to fluocinolone acetonide 0.19 mg in diabetic macular edema evaluated as the area-under-the-curve (abstract 15) |
| Dr Maria Vittoria Cicinelli, Milan | |
| 16.26 | Free-registration award-winning abstract for young scientist |
| Macular function and structure in early diabetic retinopathy (abstract 87) | |
| VIRTUAL PRESENTATION | |
| Dr Jae Yee Ku, Liverpool | |
| 16:37 | Session conclusions by the moderators |
| 16:40 | Break |
| 16:55 | Key note lecture: Diabetic eye screening: one size does not fit all |
| VIRTUAL PRESENTATION | |
| Professor Einar Stefánsson, Reykjavik | |
| 17:25 | Annual General Meeting |
| EASDec Board | |
| 18:00 | End of the day |
| 19:00 | Conference dinner |
| Restaurant Nordatlanten (North Atlantic Restaurant) | |
| Nordatlantisk promenade 1 (1.8 kilometer walk from conference venue) | |
| Dress code: Smart casual | |
| Social event registration needed for participation | |
| 19:00 We meet at the conference venue and walk through the city to the restaurant 19:30 Arrival and welcome drink 20:00 Conference dinner 22:00 Coffee 22:30 Live band: Lasse Skov & Clazified 01:15 Late night snack 02:00 End of night |
SATURDAY, 30TH OCTOBER 2021
| 08:15 | Registration |
| 08:45 | Session 5: Providing ocular and systemic prevention and care in diabetes |
| Chairs: Professor Rafael Simó, Barcelona, and Professor Kurt Højlund, Odense | |
| 08:46 | Free-registration award-winning abstract for young scientist |
| Early worsening of retinopathy in people with diabetes after rapid improvement in glycaemic control: a systematic review (abstract 46) | |
| VIRTUAL PRESENTATION | |
| Dr Handan Akil, Liverpool | |
| 08:57 | MFAP4 immunotherapy-mediated inhibition of retinal neovascularization and vascular leakage (abstract 17) |
| Dr Anders Schlosser, Odense | |
| 09:08 | Diabetic retinopathy and skin tissue advanced glycation end products are biomarkers of vascular events in type 2 diabetic patients: results of the “PRECISED” study (abstract 22) |
| Ms Alejandra Planas, Barcelona | |
| Free-registration award-winning abstract for young scientist | |
| 09:19 | Long-term visual outcomes and morphologic biomarkers of vision loss in eyes with diabetic macular edema treated with anti-VEGF therapy (abstract 106) |
| VIRTUAL PRESENTATION | |
| Dr Enrico Borrelli, Milan | |
| 09:30 | Session conclusions by the moderators |
| 09:33 | Mini Symposium: Diabetic retinopathy in relation to ocular and systemic disease: pearls and pitfalls from a Danish national registry-linkage study |
| Chair: Professor Jakob Grauslund, Odense | |
| Expert panel: Professor Kurt Højlund (the diabetologist), Professor Tunde Peto (the ophthalmologist) | |
| 09:34 | The Ocular And Systemic complications In diabetic retinopathy Study (OASIS): study design and methodology |
| Professor Jakob Grauslund, Odense | |
| 09:42 | Rapid fire presentation 1: DR as a marker of neurodegenerative disease |
| Dr Frederik Nørregaard Pedersen, Odense | |
| 09:48 | Rapid fire presentation 2: DR as a marker of cardiovascular disease |
| Ms Lonny Stokholm, Odense | |
| 09:54 | Rapid fire presentation 3: DR as a marker of ocular disease |
| Dr Sebastian Dinesen, Odense | |
| 10:00 | Panel discussion: what can be learned from big data, register-linking studies? |
| 10:10 | Keynote Lecture: A journey through multi-omics analyses of diabetic retinopathy |
| Associate Professor Patrice Fort, Ann Arbor | |
| 10:55 | Coffee Break |
| 11:15 | Session 6: Novel methods in retinal imaging |
| Chairs: Professor Tunde Peto, Belfast, and Professor Jakob Grauslund, Odense | |
| 11:16 | OCTA metrics monitor severity progression of diabetic retinopathy (abstract 29) |
| Professor José Cunha-Vaz, Coimbra | |
| 11:27 | Ganglion cell-inner plexiform layer alteration in the initial stages of diabetic retinopathy in type 2 diabetic patients: a 5-year longitudinal study (abstract 42) |
| Dr Inês Marques, Coimbra | |
| 11:38 | Microaneurysm Turnover in eyes with mild nonproliferative diabetic retinopathy is associated with progression and development of sight-threatening complications: a 5-year longitudinal study (abstract 100) |
| Dr Ana Rita Santos, Coimbra | |
| 11:49 | Three-year OCT-angiography evaluation in patients with diabetes mellitus type 1 and 2 without clinical signs of diabetic retinopathy and with good glycemic control (abstract 62) |
| Dr Stela Vujosevic, Milan | |
| 12:00 | Session conclusions by the moderators |
| 12:03 | Session 7: Entering the era of artificial intelligence in diabetic eye screening |
| Chairs: Professor Frank Verbraak, Amsterdam, and Professor Rajeeth Savarimuthu, Odense | |
| 12:04 | Development of an artificial intelligence-based diabetic retinopathy screening tool for OPTOS ultra-widefield imaging (abstract 107) |
| Professor Tunde Peto, Belfast | |
| 12:15 | Trustworthy AI: closing the gap between development and integration of AI in Ophthalmology (abstract 66) |
| Ms Cristina González-Gonzalo, Amsterdam | |
| 12:26 | Accuracy of a diabetic retinopathy grading algorithm used with a hand-held fundus camera in Southern Malawi (abstract 99) |
| VIRTUAL PRESENTATION | |
| Dr Joe Aslan, Zomba | |
| 12:37 | Testing of thirteen artificial intelligence algorithms for diabetic retinopathy using fundus images from Finland (abstract 69) |
| Dr Petri Huhtinen, Oulo | |
| 12:48 | Session conclusions by the moderators |
| 12:51 | Best poster prize ceremony and closing remarks |
| President of EASDec, Professor Rafael Simó, Barcelona | |
| 13:00 | Conference close and lunch to go |